The bump had been present for about 3 months. The patient’s mother said there had been no bleeding, tenderness, color change, ...
Melanoma remains the most aggressive and lethal form of skin cancer, characterized by a high mutational burden and complex signaling dysregulation. Over the ...
Appropriate use of immune checkpoint inhibitors and immunotherapy differs in adults with unresectable, metastatic cutaneous ...
Circulating tumor DNA levels a few weeks after immunotherapy initiation could help identify patients with melanoma at greatest risk for recurrence or death.A retrospective analysis showed individuals ...
As nonprofit-governed Servier continues to make gains with its IDH-mutant glioma med Voranigo, the drugmaker is wading deeper into the rare oncology arena with a new M&A play. | Servier on Friday ...
Clinical utility may be greatest with careful patient selection, given frailty-associated toxicity and potential endpoint inflation in indolent tumors, warranting larger validation cohorts and ...
In an interview, Vincent Ma, MD, discussed how ctDNA levels after the first cycle of immune checkpoint inhibitor in melanoma ...
Morning Overview on MSN
How gene mutations disrupt cell growth and trigger cancer?
Cancer begins when mutations in specific genes override the body’s built-in controls on cell division, allowing rogue cells ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI ® (encorafenib) in combination with cetuximab ...
Within the first year of treatment, oral anticoagulants were associated with a reduced risk for progression of 60% and a reduced risk for death of 76%. Patients with advanced melanoma who received ...
Among patients with melanoma treated with B-Raf serine-threonine kinase and/or Mitogen-activated protein kinase inhibitors, more than 60% of adverse events were associated with dabrafenib and ...
SAN FRANCISCO -- Including encorafenib (Braftovi) and cetuximab (Erbitux) in the first-line treatment of BRAF V600E-mutated metastatic colorectal cancer led to a significant improvement in overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results